Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman July 15, 2026
Rectify Pharmaceuticals Presents New Translational Data at EASL 2026 Supporting RTY-406, its Clinical Candidate for the Treatment of Primary Sclerosing Cholangitis May 27, 2026
Rectify Pharmaceuticals to Present Preclinical Data on New Dual Targeted ABCB4/BSEP Positive Functional Modulator at EASL 2026 May 18, 2026
Rectify and Boehringer Ingelheim Collaborate to Advance First-in-class Treatments for Chronic Kidney Disease December 22, 2025
